XOMA Corporation Receives Upgrade from MLV & Co. and Amicus Therapeutics Reports Positive Migalastat Trial Results
XOMA Corporation (NASDAQ: XOMA) has received an upgrade from MLV & Co. According to a report, MLV & Co. analyst Craig Suvannavejh upgraded the stock to a buy from hold. He has reiterated his price target of $7 for shares. The evaluation has been partly based on optimism surrounding expected positive data from XOMA's P3 EYEGUARD-B trial involving gevokizumab for Behcet's uveitis. XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal